Nursing women are excluded from this study because there is an unknown but potential risk of AEs in nursing infants secondary to treatment of the mother with pembrolizumab, personalized neoantigen peptides, and adjuvant.
Pregnant or breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with bevacizumab; these potential risks may also apply to other agents used in this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with eribulin; these potential risks may also apply to other agents used in this study.
The effects of prexasertib and LY on the developing human fetus are unknown. For this reason, pregnant women are excluded from this study. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with prexasertib and LY, breastfeeding women are also excluded.
Pregnant women are excluded from this study because MCS, dabrafenib and trametinib are anti-cancer agents with the potential for teratogenic or abortifacient effects. Pregnancy status will be verified at various points in the trial and a serum pregnancy test will be required. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with MCS, dabrafenib or trametinib, breastfeeding should be discontinued if the mother is treated with MCS, dabrafenib or trametinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with LY; these potential risks may also apply to the other agents used in this study
Lactating or breastfeeding women are excluded, breastfeeding should be discontinued prior to being treated with AZD; these potential risks may also apply to other agents used in this study
Pregnant women are excluded from this study because AdHER DC vaccine may have the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with AdHER DC vaccine, breastfeeding should be discontinued if the mother is treated with AdHER DC vaccine
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with PTX-; these potential risks may also apply to other agents used in this study
Pregnant women are excluded from this study because of the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother, breastfeeding should be discontinued during the study and for at least  months after last dose of study drugs. These potential risks may also apply to other agents used in this study. Women of child-bearing potential who do not agree to use adequate contraceptive measures during study therapy and for at least  months after the completion of study therapy will be excluded. Should a patient become pregnant or suspect she is pregnant while she is participating in this study, the patient should inform the treating physician immediately
Pregnant women are excluded from this study because topotecan and temozolomide are class D agents with the potential for teratogenic or abortifacient effects and because the effects of M on the developing human fetus are currently unknown. In addition, because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with topotecan, temozolomide or M, breastfeeding should be discontinued if the mother is treated with these agents
Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with olaparib, breastfeeding should be discontinued if the mother is treated with olaparib
Pregnant or breastfeeding women are excluded from this study because CAR-T cell therapy may be associated with the potential for teratogenic or abortifacient effects. Women of child bearing potential must have a negative serum pregnancy test. Because there is an unknown, but potential risk for adverse events in nursing infants secondary to treatment of the mother with CAR-T cells, breastfeeding should be discontinued. These potential risks may also apply to other agents used in this study.
Active pregnancy or breast-feeding: pregnant women are excluded from this study because the effects of osimertinib on the development of the fetus are unknown, and there is potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with osimertinib, breastfeeding should be discontinued if the mother is treated with these agents
Women who are breast-feeding or pregnant as evidenced by positive serum or urine pregnancy test performed within  hours of first dosing. (Pregnant women are excluded from this study because it is not known whether IACS- has the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with IACS- breastfeeding should be discontinued if the mother is treated with IACS-.)
Pregnant women are excluded from this study because INCB, dabrafenib, and trametinib may have teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with the study drugs, breastfeeding should be discontinued prior to the mother being treated with the study drugs.
Pregnant women are excluded from this study because meclizine is class B agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with meclizine, breastfeeding should be discontinued if the mother is treated with meclizine.
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AZD; these potential risks may also apply to other agents used in this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with either of those agents; these potential risks may also apply to other agents used in this study
Pregnant women are excluded from this study because the agent used in this study has the potential for teratogenic or abortifacient effects. Because there is a potential risk for adverse events in nursing infants secondary to treatment of the mother with the chemotherapy agents, breastfeeding should also be avoided
Breastfeeding should be discontinued if the mother is treated with LMB-; these potential risks may also apply to other agents used in this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with these agents; these potential risks may also apply to other agents used in this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the\r\nmother is treated with ramucirumab; these potential risks may also apply to other agents used in this study
Breastfeeding should be discontinued if the mother is treated with pomalidomide; these potential risks may also apply to other agents used in this study
Pregnant women are excluded from this study because the agents used in this study have the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with these agents, breastfeeding should be discontinued if the mother is being treated on this trial.
Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with lapatinib of bevacizumab, breastfeeding should be discontinued if the mother is treated on this study
Pregnant women are excluded from this study because it is unknown if STA- has the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk of adverse events in nursing infants secondary to treatment of the mother STA-, breastfeeding should be discontinued if the mother is treated with STA-; these potential risks may also apply to other agents used in this study
Nursing mothers declining to discontinue breastfeeding are excluded because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with temozolomide.
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with M (VX); these potential risks may also apply to other agents used in this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AMG ; these potential risks may also apply to other agents used in this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ABT-; these potential risks may also apply to other agents used in this study
Pregnant women are excluded from this study, breastfeeding should be discontinued if the mother is treated with VX-; these potential risks also apply to the other agents used in this study, such as carboplatin and gemcitabine
Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with vemurafenib, breastfeeding must be discontinued prior to treatment day  of the study
Pregnant women are excluded from this study; women who are breast feeding their infants should discontinue this practice if the mother is treated with ruxolitinib
Pregnant or lactating women are excluded from this study because temsirolimus and sorafenib are drugs with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with temsirolimus or sorafenib, breastfeeding should be discontinued if the mother is receiving temsirolimus/sorafenib treatment
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with IL-; these potential risks may also apply to other agents used in this study
Pregnant women are excluded from this study; breastfeeding must be discontinued if the mother is treated with AZD and cisplatin; these potential risks may also apply to other agents used in this study
Nursing women are excluded from this study because there is an unknown but potential risk of adverse events in nursing infants secondary to treatment of the mother with nivolumab, personalized neoantigen peptides, and Poly-ICLC.
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with dasatinib; potential risks may also apply to other agents used in this study
PHASE I: Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ruxolitinib; potential risks may also apply to other agents used in this study
Pregnant or lactating females. Because there is a potential risk for adverse events nursing infants secondary to treatment of the mother with carfilzomib in combination with lenalidomide. These potential risks may also apply to other agents used in this study
Pregnant women are excluded from this study because indoximod is an immunoregulatory agent with the potential for abortifacient effects due to fetal rejection by the maternal immune system. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with indoximod, breastfeeding should be discontinued if the mother is treated with indoximod. Also, docetaxel and paclitaxel are category D cytotoxic agents and are not administered to pregnant females.
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with bevacizumab; these potential risks may also apply to other agents used in this study
Pregnant women are excluded from this study because ionizing radiation is a known teratogen, and temozolomide is a class D agent with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with temozolomide, breastfeeding should be discontinued if the mother is treated with temozolomide
Pregnant women are excluded from this study. mFOLFIRINOX is a regimen containing more than one chemotherapy agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with FOLFIRINOX, breastfeeding should be discontinued if the mother is treated with these agents. These potential risks may also apply to other agents used in this study.
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ganetespib; these potential risks may also apply to other agents used in this study
Pregnant or breastfeeding women are excluded from this study because tretinoin is a retinoid derivative agent with the potential for teratogenic or abortifacient effects; because there is an unknown, but potential risk for adverse events in nursing infants secondary to treatment of the mother with tretinoin, breastfeeding should be discontinued if the mother is treated with tretinoin; these potential risks may also apply to other agents used in this study
Pregnant and lactating women are excluded from the study because the risks to an unborn fetus or potential risks in nursing infants are unknown.
Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with bevacizumab, cobimetinib, and vemurafenib, female participants who are breastfeeding must agree to discontinue nursing prior to Day  of the study.
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with CUDC-; these potential risks may also apply to other agents used in this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MVA-brachyury-TRICOM; these potential risks may also apply to other agents used in this study
Pregnant (positive pregnancy test) and lactating women are excluded from the study because the risks to an unborn fetus or potential risks in nursing infants are unknown.
Patients who are nursing infants: breastfeeding should be discontinued if the mother is treated with the study agents
Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with everolimus or bevacizumab, breastfeeding should be discontinued if the mother is treated on this study
Participants who are breastfeeding are excluded because there is an unknown but potential risk for adverse events in nursing infants secondary to contrast administration in the mother.
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with isoquercetin; these potential risks may also apply to other agents used in this study
RECIPIENT: Pregnant women and women who are lactating. The risks of CMV?MVA?Triplex to pregnant women are unknown. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother. Breastfeeding should be discontinued if the mother is enrolled on this study
Known pregnancy or breast feeding; pregnant women are excluded as the effects of F-FLT on the fetus are not known, and there is the potential for teratogenic or abortifacent effects; within  hours prior to a PET scan, a pregnancy test will be obtained in all female participants of child bearing potential to confirm non-pregnant status; because there is an unknown, but potential, risk of adverse effects in nursing infants, breastfeeding should be discontinued before the mother receives F-FLT
Lactation should be suspended for at least two days following the administration of [F] FAZA to the mother, because of the unknown but potential risk for adverse events in nursing infants secondary to administration of the radionuclide to a lactating woman.
Pregnant women are excluded from this study because chemoradiotherapy has the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to the use of ferumoxytol as a contrast agent in the mother, breastfeeding should be discontinued if the mother receives ferumoxytol while nursing; men who are sexually active and not willing/able to use medically acceptable forms of contraception are also excluded from this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother has been exposed to L-[methyl-C]methionine; these potential risks may also apply to other agents used in this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with nivolumab and ipilimumab; these potential risks may also apply to blinatumomab
